AA
NRIX icon

AlphaCentric Advisors’s Nurix Therapeutics NRIX Stock Holding History

AlphaCentric Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$627K Buy
25,845
+274
+1% +$4.67K 0.53% 64
2026
Q1 		$396K Buy
25,571
+7,437
+41% +$123K 0.4% 88
2025
Q4 		$344K Buy
+18,134
New +$261K 0.34% 93

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AlphaCentric Advisors's NRIX Position: Q2 2026 in Review

AlphaCentric Advisors increased its Nurix Therapeutics (NRIX) stake by 1.1% in Q2 2026, buying an estimated $4.67K and bringing the position to 25,845 shares worth $627K. The position accounts for 0.53% of the portfolio, ranked #64.

AlphaCentric Advisors first reported a position in NRIX in Q4 2025 and has held it in 3 quarters since. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • AlphaCentric Advisors held 25,845 shares of Nurix Therapeutics worth $627K as of Q2 2026.
  • AlphaCentric Advisors bought 274 Nurix Therapeutics shares in Q2 2026, an estimated $4.67K.
  • Nurix Therapeutics made up 0.53% of AlphaCentric Advisors's portfolio in Q2 2026, its #64 holding.
  • AlphaCentric Advisors first reported a position in Nurix Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.